Abstract | BACKGROUND: OBJECTIVE: The aim was to evaluate the efficacy and safety of CBD as adjunctive treatment for seizures in patients with LGS using meta-analytical techniques. METHODS: Randomized, placebo-controlled, single- or double-blinded trials were identified. Main outcomes included the ≥ 50% reduction in baseline drop and non-drop seizure frequency, and the incidence of treatment withdrawal and adverse events (AEs). Risk ratios (RRs) with 95% confidence intervals (CIs) were estimated through the inverse variance method. RESULTS: Two trials were included involving 396 participants. Patients presenting ≥ 50% reduction in drop seizure frequency during the treatment were 40.0% with CBD and 19.3% with placebo [RR 2.12 (95% CI 1.48-3.03); p < 0.001]. The rate of non-drop seizure frequency was reduced by 50% or more in 49.4% of patients in the CBD and 30.4% in the placebo arms [RR 1.62 (95% CI 1.09-2.43); p = 0.018]. The RR for CBD withdrawal was 4.93 (95% CI 1.50-16.22; p = 0.009). The RR to develop any AE during CBD treatment was 1.24 (95% CI 1.11-1.38; p < 0.001). AEs significantly associated with CBD were somnolence, decreased appetite, diarrhea and increased serum aminotransferases. CONCLUSIONS: Adjunctive CBD resulted in a greater reduction in seizure frequency and a higher rate of AEs than placebo in patients with LGS presenting seizures uncontrolled by concomitant AEDs.
|
Authors | Simona Lattanzi, Francesco Brigo, Claudia Cagnetti, Eugen Trinka, Mauro Silvestrini |
Journal | CNS drugs
(CNS Drugs)
Vol. 32
Issue 10
Pg. 905-916
(10 2018)
ISSN: 1179-1934 [Electronic] New Zealand |
PMID | 30132269
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Chemical References |
- Anticonvulsants
- Cannabidiol
- Transaminases
|
Topics |
- Anticonvulsants
(therapeutic use)
- Cannabidiol
(adverse effects, therapeutic use)
- Double-Blind Method
- Humans
- Lennox Gastaut Syndrome
(drug therapy, metabolism)
- Odds Ratio
- Randomized Controlled Trials as Topic
- Seizures
(drug therapy, metabolism)
- Transaminases
(metabolism)
|